Inflammatory Targeting, Small Molecules & Peptides
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
60
NCT05164393
Phase I/IIa Trial to Evaluate AVX001 Gel in Doses of 1% or 3% Compared With Vehicle Over Four Weeks of Field-directed Treatment Period in Adult Subjects With AK
Phase: Phase 1/2
Role: Lead Sponsor
Start: Nov 2, 2021
Completion: Mar 31, 2022
Loading map...